Eli Lilly and Co
XHAM:LLY
Eli Lilly and Co
XHAM:LLY
Price:
846.2
EUR
-1.71%
Market Closed
Market Cap:
€809.5B
Relative Value
The Relative Value of one
LLY
stock under the Base Case scenario is
315.53
EUR.
Compared to the current market price of 846.2 EUR,
Eli Lilly and Co
is
Overvalued by 63%.
Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Relative Valuation FAQ:
LLY
Relative Value
Base Case
315.53
EUR
Overvaluation 63%
Multiples Across Competitors
LLY Competitors Multiples
Eli Lilly and Co Competitors
Eli Lilly and Co Competitors
All Countries
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| US |
|
Eli Lilly and Co
XHAM:LLY
|
867.4B EUR | 13.3 | 42 | 28.4 | 30.3 | |
| US |
|
Johnson & Johnson
NYSE:JNJ
|
571.4B USD | 6.1 | 21.3 | 14.8 | 18.2 | |
| CH |
|
Roche Holding AG
SIX:ROG
|
257.8B CHF | 4.2 | 20 | 11.8 | 13.3 | |
| UK |
|
AstraZeneca PLC
LSE:AZN
|
220.3B GBP | 5 | 28.9 | 16 | 22.6 | |
| CH |
|
Novartis AG
SIX:NOVN
|
228.9B CHF | 5.2 | 21.1 | 13.1 | 16.8 | |
| US |
|
Merck & Co Inc
NYSE:MRK
|
283.3B USD | 4.4 | 15.5 | 9.6 | 11.7 | |
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
240.1B USD | 103.6 | -82.1 | 380.1 | 953.2 | |
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.1T DKK | 3.5 | 10.5 | 7.8 | 9.1 | |
| US |
|
Pfizer Inc
NYSE:PFE
|
155.3B USD | 2.5 | 20 | 7.7 | 10.2 | |
| US |
|
Bristol-Myers Squibb Co
NYSE:BMY
|
119.5B USD | 2.5 | 17 | 7.1 | 8.8 | |
| UK |
|
GSK plc
XETRA:GS71
|
94.9B EUR | 2.5 | 14.3 | 7.9 | 9.9 |
P/S Multiple
P/E Multiple
EV/EBITDA Multiple
EV/EBIT Multiple
